Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)

Ankylosing Spondylitis Clinical Trial

— METALL  

Official title:

Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01790022
• Other study ID #: METALL 2012
• Status: Active, not recruiting
• Phase: Phase 2
• First received: February 9, 2013
• Last updated: February 9, 2013
• Start date: July 2012

Study information

• Verified date: February 2013
• Source: Saratov State Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russia: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

In this study, efficacy of methylprednisolone in reduction of signs and symptoms (back pain, stiffness, joint pain and swelling) of active ankylosing spondylitis (AS) will be investigated. It is expected, that a single dose of methylprednisolone 500 mg given intravenously at baseline will lead to a rapid reduction of symptoms of active AS, which can be seen already 2 weeks after drug administration.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age of =18 years.

• Definite diagnosis of AS according to the modified New York criteria.

• History of an inadequate response to =2 nonsteroidal antiinflammatory drugs (NSAIDs) taken for at least 2 weeks each or NSAIDs intolerance.

• Active disease as defined by the Bath Ankylosing Spondylitis DIsease Activity Index (BASDAI) value of =4 at screening despite concomitant treatment with an NSAID or without NSAIDs in case of intolerance.

Exclusion Criteria:

• The female subject is pregnant or lactating.

• Patients with other chronic inflammatory articular disease or systemic autoimmune disease.

• History of inadequate response to previous anti-tumour necrosis factor (TNF) a therapy.

• Treatment with any other investigational drug within 4 weeks of 5 half-life of the drug (whichever is longer) prior to baseline.

• Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks with a standard cholestyramine wash-out).

• Treatment with intravenous, intramuscular or intraarticular/periarticular steroids within 4 weeks prior to screening.

• History of oesophageal, gastric, duodenal or intestinal ulceration, clinically relevant gastrointestinal bleeding.

• History of or current signs of coronary heart disease, myocardial infarction, stroke or transient ischemic attack, peripheral arterial thrombotic events.

• Congestive heart failure (NYHA III-IV)

• Uncontrolled arterial hypertension.

• History of diabetes mellitus.

• History of glaucoma.

• Major surgery within 12 weeks prior to screening.

• Evidence of any other severe uncontrolled gastrointestinal, hepatic, renal, pulmonary, cardiovascular, nervous or endocrine disorders.

• Any active current viral, bacterial or fungal infection, a history of recurrent clinically significant infection, infections requiring treatment with antibiotics within 4 weeks prior to baseline.

• History of chronic infection with hepatitis B or C, history of HIV infection.

• Primary or secondary immunodeficiency.

• Any other conditions making the patient unsuitable in the opinion of the investigator for the participation in the current study.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Drug:
• Methylprednisolone

Locations

Country	Name	City	State
Russian Federation	Department of Rheumatology, Saratov Region Hospital	Saratov

Sponsors (2)

Lead Sponsor	Collaborator
Saratov State Medical University	Charite University, Berlin, Germany

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Assessment of Spondyloarthritis International Society 40 (ASAS40) response	The Assessment of Spondyloarthritis International Society 40 (ASAS40) response is defined as an improvement of =40% and =2 points in at least 3 out of four following domains (and no worsening in remaining domain): Patient global; Pain; Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI); Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)	Week 2	No